Bio-Path shares are trading higher after the company announced the presentation of data from its ongoing Phase 2 combination study of prexigebersen for the treatment of acute myeloid leukemia at the ASCO Annual Meeting.
Portfolio Pulse from Benzinga Newsdesk
Bio-Path shares are trading higher following the announcement of data presentation from its ongoing Phase 2 study of prexigebersen for acute myeloid leukemia at the ASCO Annual Meeting.
June 03, 2024 | 2:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Path shares are trading higher after the company announced the presentation of data from its ongoing Phase 2 combination study of prexigebersen for the treatment of acute myeloid leukemia at the ASCO Annual Meeting.
The presentation of positive data from a Phase 2 study at a major conference like the ASCO Annual Meeting is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100